Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serum Folate Receptor Induction in Ovarian Cancer
NCT02520115Phase 1Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Aug 2015
- Primary completion
- Sep 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of valproic acid and dexamethasone in ovarian carcinoma and adnexal mass (2 arms), sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoints: Ability to increase serum Folate Receptor (FR) levels, Utility of serum FR to distinguish between patients with benign masses or malignancy and 2 more. Started Aug 2015; status: completed.
02
Drugs
valproic aciddexamethasone
03
Conditions
ovarian carcinomaadnexal mass
Beyond the preview
Go deeper on NCT02520115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520115.